Greenwich Lifesciences 在2026年ASCO会议上公布Flamingo-01三期试验开放标签数据

美股速递
Jun 01

Greenwich Lifesciences 公司近期在2026年美国临床肿瘤学会年会上,公布了其关键性Flamingo-01三期临床试验的开放标签数据。这项研究成果的发布,标志着公司在肿瘤免疫治疗领域取得了新的进展,为后续的临床开发与监管申请提供了重要依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10